Abstract：
UNASSIGNED: Cyclosporine A (CsA) and regular doses of recombinant human thrombopoietin (rhTPO) can accelerate platelet recovery in patients with non-severe aplastic anemia (NSAA). However, it is unclear whether CsA plus rhTPO at a higher dose can further increase the efficacy.
UNASSIGNED: Data from patients with newly diagnosed NSAA, who had been treated with CsA in combination with different doses of rhTPO between February 2021 and August 2021 at Peking Union Medical College Hospital, were reviewed. All the enrolled patients had been treated with CsA at 3-5 mg/(kg/d), and patients were further classified into high-dose (with rhTPO 30000U qd × 14 days for 2 months) group or regular-dose (with rhTPO 15000U qd × 7days for 3 months) group. The treatment response and therapy-related adverse events were compared.
UNASSIGNED: 36 patients including 16 (44.4%) in the high-dose and 20 (55.6%) in the regular-dose group were enrolled. The baseline characteristics were compatible between the two groups. The platelet counts were significantly higher at 1/3/6 months in the high-dose group (p = 0.028, 0.0063 and p = 0.040, respectively). The high-dose group had a significantly shorter time to platelet transfusion independence ([1 (0.5-6) months vs 2.5 (1-12) months, p = 0.040]). There was no significant difference in overall response and complete response rate between the two groups at 1/3/6/12 months (p > 0.05). Treatment-related morbidities were similar between the two groups (p > 0.05).
UNASSIGNED: Adding a higher dose of rhTPO can further accelerate platelet recovery and platelet transfusion independence in patients with newly diagnosed NSAA.
UNASSIGNED: Data from patients with newly diagnosed NSAA, who had been treated with CsA in combination with different doses of rhTPO between February 2021 and August 2021 at Peking Union Medical College Hospital, were reviewed. All the enrolled patients had been treated with CsA at 3-5 mg/(kg/d), and patients were further classified into high-dose (with rhTPO 30000U qd × 14 days for 2 months) group or regular-dose (with rhTPO 15000U qd × 7days for 3 months) group. The treatment response and therapy-related adverse events were compared.
UNASSIGNED: 36 patients including 16 (44.4%) in the high-dose and 20 (55.6%) in the regular-dose group were enrolled. The baseline characteristics were compatible between the two groups. The platelet counts were significantly higher at 1/3/6 months in the high-dose group (p = 0.028, 0.0063 and p = 0.040, respectively). The high-dose group had a significantly shorter time to platelet transfusion independence ([1 (0.5-6) months vs 2.5 (1-12) months, p = 0.040]). There was no significant difference in overall response and complete response rate between the two groups at 1/3/6/12 months (p > 0.05). Treatment-related morbidities were similar between the two groups (p > 0.05).
UNASSIGNED: Adding a higher dose of rhTPO can further accelerate platelet recovery and platelet transfusion independence in patients with newly diagnosed NSAA.
摘要：
■环孢素A（CsA）和常规剂量的重组人血小板生成素（rhTPO）可以加速非重度再生障碍性贫血（NSAA）患者的血小板恢复。然而,尚不清楚CsA联合rhTPO在较高剂量下是否能进一步提高疗效.
■来自新诊断的NSAA患者的数据，2021年2月至2021年8月在北京协和医院接受CsA联合不同剂量rhTPO治疗，被审查了。所有入选患者均接受CsA3-5mg/（kg/d）治疗，将患者进一步分为高剂量（rhTPO30000Uqd×14天，持续2个月）组和常规剂量（rhTPO15000Uqd×7天，持续3个月）组。比较治疗反应和治疗相关不良事件。
■纳入36例患者，其中高剂量组16例（44.4%），常规剂量组20例（55.6%）。两组基线特征一致。高剂量组的血小板计数在1/3/6个月时显著升高(分别为p=0.028、0.0063和p=0.040)。高剂量组的血小板输注独立时间明显缩短（[1（0.5-6）个月比2.5（1-12）个月，p=0.040])。两组在1/3/6/12个月时的总体缓解率和完全缓解率无显著差异(p>0.05)。两组治疗相关的发病率相似(p>0.05)。
■添加更高剂量的rhTPO可以进一步加速新诊断NSAA患者的血小板恢复和血小板输注独立性。
■来自新诊断的NSAA患者的数据，2021年2月至2021年8月在北京协和医院接受CsA联合不同剂量rhTPO治疗，被审查了。所有入选患者均接受CsA3-5mg/（kg/d）治疗，将患者进一步分为高剂量（rhTPO30000Uqd×14天，持续2个月）组和常规剂量（rhTPO15000Uqd×7天，持续3个月）组。比较治疗反应和治疗相关不良事件。
■纳入36例患者，其中高剂量组16例（44.4%），常规剂量组20例（55.6%）。两组基线特征一致。高剂量组的血小板计数在1/3/6个月时显著升高(分别为p=0.028、0.0063和p=0.040)。高剂量组的血小板输注独立时间明显缩短（[1（0.5-6）个月比2.5（1-12）个月，p=0.040])。两组在1/3/6/12个月时的总体缓解率和完全缓解率无显著差异(p>0.05)。两组治疗相关的发病率相似(p>0.05)。
■添加更高剂量的rhTPO可以进一步加速新诊断NSAA患者的血小板恢复和血小板输注独立性。
